335 related articles for article (PubMed ID: 21285173)
21. [Comparison of effects of various therapeutic methods of the urinary system in patients with gout. Observations on 195 patients with gout].
Kawenoki-Minc E; Eyman E; Weryńska-Przybylska J; Brzozowska AM
Reumatologia; 1977; 15(2):199-206. PubMed ID: 897378
[No Abstract] [Full Text] [Related]
22. Individualising the dose of allopurinol in patients with gout.
Kannangara DRW; Graham GG; Wright DFB; Stocker SL; Portek I; Pile KD; Barclay ML; Williams KM; Stamp LK; Day RO
Br J Clin Pharmacol; 2017 Sep; 83(9):2015-2026. PubMed ID: 28417592
[TBL] [Abstract][Full Text] [Related]
23. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
24. Gout: joint pain and more.
Harv Mens Health Watch; 2007 Dec; 12(5):1-3. PubMed ID: 18225332
[No Abstract] [Full Text] [Related]
25. Gout due to xanthine derivatives.
Toda K; Goriki K; Ochiai M; Tokunou H; Uehara S; Takahashi H; Okusaki K
Br J Rheumatol; 1997 Oct; 36(10):1131-2. PubMed ID: 9374937
[No Abstract] [Full Text] [Related]
26. Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout.
Kankam M; Hall J; Gillen M; Yang X; Shen Z; Lee C; Liu S; Miner JN; Walker S; Clauson V; Wilson D; Nguyen M
J Clin Pharmacol; 2018 Sep; 58(9):1214-1222. PubMed ID: 29733447
[TBL] [Abstract][Full Text] [Related]
27. Drugs in the treatment of hyperuricemia.
Elion GB
Adv Nephrol Necker Hosp; 1974; 3():51-7. PubMed ID: 4219708
[No Abstract] [Full Text] [Related]
28. [Allopurinol in the treatment of gout].
Klein G; Griendl W; Kalb R
Z Rheumaforsch; 1968 Dec; 27(11):455-60. PubMed ID: 5710881
[No Abstract] [Full Text] [Related]
29. Difference of the plasma concentration and urinary excretion of allopurinol, oxypurinol, and purine bases between dietary intake and fasting.
Yamamoto T; Moriwaki Y; Takahashi S; Tsutsumi Z; Yamakita J; Higashino K
Int J Clin Pharmacol Ther; 1996 Apr; 34(4):157-62. PubMed ID: 8861734
[TBL] [Abstract][Full Text] [Related]
30. A population pharmacokinetic model to predict oxypurinol exposure in patients on haemodialysis.
Wright DF; Doogue MP; Barclay ML; Chapman PT; Cross NB; Irvine JH; Stamp LK
Eur J Clin Pharmacol; 2017 Jan; 73(1):71-78. PubMed ID: 27683090
[TBL] [Abstract][Full Text] [Related]
31. Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration.
Stamp LK; Chapman PT; Barclay M; Horne A; Frampton C; Merriman TR; Wright DFB; Drake J; Dalbeth N
Clin Transl Sci; 2020 Jan; 13(1):110-115. PubMed ID: 31444839
[TBL] [Abstract][Full Text] [Related]
32. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
33. The effect of benzbromarone on allopurinol/oxypurinol kinetics in patients with gout.
Müller FO; Schall R; Groenewoud G; Hundt HK; van der Merwe JC; van Dyk M
Eur J Clin Pharmacol; 1993; 44(1):69-72. PubMed ID: 8436158
[TBL] [Abstract][Full Text] [Related]
34. Improving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapy.
Keith MP; Gilliland WR
Clin Pharmacol Ther; 2011 Sep; 90(3):363-4. PubMed ID: 21862966
[TBL] [Abstract][Full Text] [Related]
35. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
Hilmi BA; Asmahan MI; Rosman A
Med J Malaysia; 2012 Feb; 67(1):125-6. PubMed ID: 22582566
[TBL] [Abstract][Full Text] [Related]
36. [Uricosuric agent].
Ohno I
Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
[TBL] [Abstract][Full Text] [Related]
37. Withdrawal of longterm antihyperuricemic therapy in tophaceous gout.
van Lieshout-Zuidema MF; Breedveld FC
J Rheumatol; 1993 Aug; 20(8):1383-5. PubMed ID: 8230024
[TBL] [Abstract][Full Text] [Related]
38. Pharmacologic approach to the maintenance of urate homeostasis.
Kelley WN
Nephron; 1975; 14(1):99-115. PubMed ID: 1091870
[TBL] [Abstract][Full Text] [Related]
39. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
[TBL] [Abstract][Full Text] [Related]
40. [How to select and use urate lowering agents for hyperuricemia].
Yamanaka H
Nihon Rinsho; 1996 Dec; 54(12):3261-5. PubMed ID: 8976102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
